Hyperlipidemia and cardiovascular risk factors in patients with type 2 diabetes

American Journal of Managed Care

Volumn 6, Issue 13 SUPPL., 2000, Pages

  Goldberg, R B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

BLOOD CLOTTING; CARDIOVASCULAR RISK; CONFERENCE PAPER; DISEASE ASSOCIATION; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR; RISK MANAGEMENT;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; MALE; MIDDLE AGED; RISK FACTORS;

EID: 0033842915     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (27)

1. Diabetes and cardiovascular disease. The Framingham Study
2. Heart disease and diabetes
3. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?
4. When does diabetes start?
5. Insulin sensitivity and atherosclerosis
6. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes
7. Lipids, glucose tolerance and vascular disease: The Framingham Study
8. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial
9. Hyperglycemia and microvascular and macrovascular disease in diabetes
10. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
11. 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin dependent diabetic and non-diabetic subjects
12. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
13. Cardiovascular events and their reduction with pravastatin diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the Cholesterol and Recurrent Events (CARE) Trial
14. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
15. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
16. Management of dyslipidemia in adults with diabetes
17. Cholesterol Management in the era of managed care
18. Hypertriglyceridemia, atherogenic hyperlipidemia and the metabolic syndrome
19. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study
20. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
21. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
22. The Diabetes Atherosclerosis Intervention Study (DAIS): A study conducted in cooperation with the World Health Organization
23. Physical and metabolic characteristics of persons with diabetes
24. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
25. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE Study and MICRO-HOPE substudy
26. Microalbuminuria: A major risk factor in non-insulin-dependent diabetes. A 10-year follow-up study of 503 patients
27. Collaborative overview of randomized trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration